These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

955 related articles for article (PubMed ID: 21361790)

  • 1. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
    Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
    Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
    Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
    Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K
    Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
    Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
    Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer targeting gene-viro-therapy specific for liver cancer by α-fetoprotein-controlled oncolytic adenovirus expression of SOCS3 and IL-24.
    Cao X; Wei R; Liu X; Zeng Y; Huang H; Ding M; Zhang K; Liu XY
    Acta Biochim Biophys Sin (Shanghai); 2011 Oct; 43(10):813-21. PubMed ID: 21835849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
    Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X
    Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
    El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
    J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma.
    Ren XW; Liang M; Meng X; Ye X; Ma H; Zhao Y; Guo J; Cai N; Chen HZ; Ye SL; Hu F
    Cancer Gene Ther; 2006 Feb; 13(2):159-68. PubMed ID: 16082383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
    Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
    Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.
    Zhang KJ; Zhang J; Wu YM; Qian J; Liu XJ; Yan LC; Zhou XM; Xiao RJ; Wang YG; Cao X; Wei N; Liu XR; Tang B; Jiao XY; Chen K; Liu XY
    Cancer Gene Ther; 2012 Sep; 19(9):619-29. PubMed ID: 22790965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.
    Zhao L; Dong A; Gu J; Liu Z; Zhang Y; Zhang W; Wang Y; He L; Qian C; Qian Q; Liu X
    Cancer Gene Ther; 2006 Nov; 13(11):1011-22. PubMed ID: 16799468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
    Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus.
    Ohashi M; Kanai F; Tateishi K; Taniguchi H; Marignani PA; Yoshida Y; Shiratori Y; Hamada H; Omata M
    Biochem Biophys Res Commun; 2001 Mar; 282(2):529-35. PubMed ID: 11401492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC.
    Pan Q; Liu B; Liu J; Cai R; Liu X; Qian C
    Acta Oncol; 2008; 47(1):135-44. PubMed ID: 17934893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy.
    Zhang Y; Gu J; Zhao L; He L; Qian W; Wang J; Wang Y; Qian Q; Qian C; Wu J; Liu XY
    Cancer Res; 2006 Apr; 66(8):4291-8. PubMed ID: 16618754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector.
    Guan M; Rodriguez-Madoz JR; Alzuguren P; Gomar C; Kramer MG; Kochanek S; Prieto J; Smerdou C; Qian C
    Cancer Res; 2006 Feb; 66(3):1620-9. PubMed ID: 16452221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice.
    Sagawa T; Yamada Y; Takahashi M; Sato Y; Kobune M; Takimoto R; Fukaura J; Iyama S; Sato T; Miyanishi K; Matsunaga T; Takayama T; Kato J; Sasaki K; Hamada H; Niitsu Y
    Hepatology; 2008 Sep; 48(3):828-40. PubMed ID: 18756484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.